市场调查报告书
商品编码
1373340
药物发现外包服务市场-按服务类型(化学、生物)、挖掘类型(小分子和大分子)、疾病模型(体外、细胞和动物模型)、治疗领域(糖尿病、神经病学、肿瘤学)、全球预测(2023-2032)Drug Discovery Outsourcing Services Market-By Service Type (Chemistry, Biological), Dug Type (Small & Large-molecule), Disease Model (In-vitro, Cellular & Animal Models), Therapeutic Area (Diabetes, Neurology, Oncology), Global Forecast (2023-2032) |
由于基因疗法和单株抗体等生物製剂的快速发展,药物发现外包服务市场规模从 2023 年到 2032 年的复合年增长率预计将达到 8.2%。
为了满足个别患者的需求,新型生物製剂和个人化医疗解决方案的蓬勃发展导致生物製药研发活动对外包服务的需求更大。举个例子,2021年1月,Charles River Laboratories International与生物製药服务提供者JADE Biomedical合作,扩大其全球生物製剂测试能力,同时满足生物製剂治疗(主要是细胞和基因疗法)的需求。外包提供者对服务的日益关注,例如现实世界的证据生成以及以患者为中心的试验设计,以提高临床研究的效率,也将有助于市场的成长。
药物发现外包服务业根据服务类型、药物类型、疾病模型、治疗领域和区域进行细分。
从服务类型来看,2023-2032年化学服务领域的市场规模将录得可观的复合年增长率。药物发现外包化学服务在製药和生物技术行业简化和加快药物开发过程中发挥关键作用。外包计算化学服务以满足虚拟筛选、分子建模和基于结构的药物设计等用途的重要性日益凸显,也将有助于该领域的成长。
以治疗领域为基础,神经病学领域的药物发现外包服务产业价值预计将扩大到2032年。这一增长可归因于阿兹海默症、帕金森氏症和多发性硬化症的更高负担以及随后的需求开发有效的治疗方法。外包神经病学药物发现服务的一些优点包括加速研发活动、降低成本以及更容易获得专业知识。
从地区来看,由于存在庞大的人才库、具有成本效益的劳动力和有利的监管环境,预计到 2032 年,亚太地区药物发现外包服务市场规模将出现显着的复合年增长率。对降低成本、获取专业知识和加速药物开发过程的日益增长的需求迫使许多製药和生物技术公司转向外包药物发现服务。与智慧财产权、临床试验和资料安全相关的不断变化的监管环境也将促进区域产业的成长。
Drug Discovery Outsourcing Services Market size is poised to record 8.2% CAGR from 2023-2032, on account of the rapid advances in biologics, including gene therapies and monoclonal antibodies.
The surging developments in novel biologics and personalized medicine solutions to cater to individual patients is leading to the greater demand for outsourcing services in biopharmaceutical R&D activities. To cite an instance, in January 2021, Charles River Laboratories International partnered with biopharma service provider JADE Biomedical to expand its global biologics testing capabilities while accommodating the demand for biologics therapeutics, mainly cell and gene therapies. The growing focus of outsourcing providers on services, such as real-world evidence generation as well as patient-centric trial designs for improved efficiency of clinical research will also contribute to the market growth.
The drug discovery outsourcing services industry is segmented based on service type, drug type, disease model, therapeutic area, and region.
In terms of service type, the market size from the chemistry services segment will record appreciable CAGR from 2023-2032. Drug discovery outsourcing chemistry services are playing pivotal role in the pharmaceutical and biotechnology industries in streamlining and expediting the drug development process. The surging importance of outsourcing computational chemistry services to cater to uses in virtual screening, molecular modeling, and structure-based drug design will also contribute to the segment growth.
On the basis of therapeutic area, the drug discovery outsourcing services industry value from the neurology segment is projected to expand up to 2032. The growth can be attributed to the higher burden of Alzheimer's disease, Parkinson's disease, and multiple sclerosis along with the subsequent need for the development of their effective treatments. Accelerated R&D activities, reduces costs, and the improved access to specialized expertise are some advantages of outsourcing neurology drug discovery services.
Regionally, the APAC drug discovery outsourcing services market size is projected to observe notable CAGR through 2032 due to the presence of large talent pools, cost-effective labor, and favorable regulatory environments. The surging need for reducing costs, accessing specialized expertise, and accelerating the drug development process has compelled numerous pharmaceutical and biotechnology companies to turn to outsourcing for drug discovery services. The evolving regulatory landscape related to intellectual property, clinical trials, and data security will also add to the regional industry growth.